Placental growth factor-1 and epithelial haemato–retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy
暂无分享,去创建一个
F. Mascarelli | P. Massin | F. Behar-Cohen | A. Glotin | J. Jeanny | Y. Kozak | N. Miyamoto | D. Benezra
[1] E. Agrón,et al. Serum inflammatory markers in diabetic retinopathy. , 2005, Investigative ophthalmology & visual science.
[2] Manju Patel,et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. , 2005, Ophthalmology.
[3] Lee M Ellis,et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells , 2005, Oncogene.
[4] H. Ozdemir,et al. Serous macular detachment in diabetic cystoid macular oedema. , 2005, Acta ophthalmologica Scandinavica.
[5] E. Scott,et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. , 2005, The Journal of clinical investigation.
[6] M. Shibuya,et al. A Novel Snake Venom Vascular Endothelial Growth Factor (VEGF) Predominantly Induces Vascular Permeability through Preferential Signaling via VEGF Receptor-1* , 2004, Journal of Biological Chemistry.
[7] M. Grant,et al. The role of growth factors in the pathogenesis of diabetic retinopathy , 2004, Expert opinion on investigational drugs.
[8] N. Mitsiades,et al. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. , 2004, The American journal of pathology.
[9] V. Peponis,et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. , 2004, Ophthalmology.
[10] A. D. de Vos,et al. The Crystal Structure of Placental Growth Factor in Complex with Domain 2 of Vascular Endothelial Growth Factor Receptor-1* , 2004, Journal of Biological Chemistry.
[11] M. Bartoli,et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives , 2003, Diabetes/metabolism research and reviews.
[12] A. Luttun,et al. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis , 2003, Cell and Tissue Research.
[13] A. Howlett,et al. A Selective and Oral Small Molecule Inhibitor of Vascular Epithelial Growth Factor Receptor (VEGFR)-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability , 2003, Journal of Pharmacology and Experimental Therapeutics.
[14] A. Luttun,et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor‐1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders , 2003, Journal of thrombosis and haemostasis : JTH.
[15] J. Rakic,et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.
[16] B. Fu,et al. Structural mechanisms of acute VEGF effect on microvessel permeability. , 2003, American journal of physiology. Heart and circulatory physiology.
[17] I. Morita,et al. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. , 2003, Biochemical and biophysical research communications.
[18] M. Shibuya,et al. VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. , 2003, Biochemical and biophysical research communications.
[19] G. Vrensen,et al. Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.
[20] D. Mottet,et al. CoCl2, a Chemical Inducer of Hypoxia‐Inducible Factor‐1, and Hypoxia Reduce Apoptotic Cell Death in Hepatoma Cell Line HepG2 , 2002, Annals of the New York Academy of Sciences.
[21] G. Amerongen,et al. Targets for pharmacological intervention of endothelial hyperpermeability and barrier function. , 2002 .
[22] T. Bensaoula,et al. Biochemical and ultrastructural studies in the neural retina and retinal pigment epithelium of STZ-diabetic rats: effect of captopril. , 2001, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[23] P. Campochiaro,et al. Retinal and choroidal neovascularization , 2000, Journal of cellular physiology.
[24] G. Vrensen,et al. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations , 2000 .
[25] T. Gardner,et al. Vascular Endothelial Growth Factor Induces Rapid Phosphorylation of Tight Junction Proteins Occludin and Zonula Occluden 1 , 1999, The Journal of Biological Chemistry.
[26] S. Kishi,et al. Patterns of diabetic macular edema with optical coherence tomography. , 1999, American journal of ophthalmology.
[27] J. Tarbell,et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. , 1998, Diabetes.
[28] N. Ferrara,et al. Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.
[29] R. Masood,et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[30] L. Hjelmeland,et al. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. , 1996, Experimental eye research.
[31] Susan Lightman,et al. Diabetic retinopathy. , 2003, Clinical cornerstone.
[32] G. Vrensen,et al. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. , 2000, Current eye research.
[33] M. Boulton,et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. , 1998, Laboratory investigation; a journal of technical methods and pathology.